CA2905594A1 - Compositions destinees a etre utilisees en traitement de troubles oculaires a l'aide de dipyridamole - Google Patents
Compositions destinees a etre utilisees en traitement de troubles oculaires a l'aide de dipyridamole Download PDFInfo
- Publication number
- CA2905594A1 CA2905594A1 CA2905594A CA2905594A CA2905594A1 CA 2905594 A1 CA2905594 A1 CA 2905594A1 CA 2905594 A CA2905594 A CA 2905594A CA 2905594 A CA2905594 A CA 2905594A CA 2905594 A1 CA2905594 A1 CA 2905594A1
- Authority
- CA
- Canada
- Prior art keywords
- dipyridamole
- eye
- composition
- topically
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 229960002768 dipyridamole Drugs 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 208000030533 eye disease Diseases 0.000 title claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 210000000795 conjunctiva Anatomy 0.000 claims description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 31
- 239000006196 drop Substances 0.000 description 29
- 210000001508 eye Anatomy 0.000 description 29
- 206010013774 Dry eye Diseases 0.000 description 28
- 238000009472 formulation Methods 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 208000031973 Conjunctivitis infective Diseases 0.000 description 11
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000009329 Graft vs Host Disease Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 208000024908 graft versus host disease Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 206010002091 Anaesthesia Diseases 0.000 description 8
- 201000002154 Pterygium Diseases 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 201000007717 corneal ulcer Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 206010064996 Ulcerative keratitis Diseases 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 229940012356 eye drops Drugs 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 206010069732 neurotrophic keratopathy Diseases 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010022941 Iridocyclitis Diseases 0.000 description 3
- 201000002287 Keratoconus Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 201000004612 anterior uveitis Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000003683 corneal stroma Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 210000003786 sclera Anatomy 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 206010010984 Corneal abrasion Diseases 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 208000000222 Viral Eye Infections Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000003366 colagenolytic effect Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 208000021921 corneal disease Diseases 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010023365 keratopathy Diseases 0.000 description 2
- 201000004768 pinguecula Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001745 uvea Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000016134 Conjunctival disease Diseases 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000014260 Fungal keratitis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010062353 Keratitis fungal Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 206010034944 Photokeratitis Diseases 0.000 description 1
- 206010062889 Pingueculitis Diseases 0.000 description 1
- 241001621636 Pterygia Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000010036 cardiovascular benefit Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 201000004356 excessive tearing Diseases 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009861 stroke prevention Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000004488 tear evaporation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention porte sur des compositions destinées à être utilisées en traitement de troubles oculaires, les compositions comprenant une quantité efficace d'un dipyridamole administré par voie topique. De préférence, le dipyridamole administré par voie topique est formulé sous forme d'une solution. De préférence, le dipyridamole administré par voie topique est au moins un agent choisi entre le dipyridamole et un sel pharmaceutiquement acceptable de celui-ci. De préférence, la quantité efficace correspond à une concentration de molarité d'au moins environ 10-5. De préférence, la quantité efficace est basée sur une administration pour traitement au moins une fois tous les deux jours.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL225179A IL225179A (en) | 2013-03-12 | 2013-03-12 | Compounds for use in ocular disorders using dipyridamole |
| IL225179 | 2013-03-12 | ||
| PCT/IB2014/059645 WO2014141079A1 (fr) | 2013-03-12 | 2014-03-11 | Compositions destinées à être utilisées en traitement de troubles oculaires à l'aide de dipyridamole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2905594A1 true CA2905594A1 (fr) | 2014-09-18 |
Family
ID=48916407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2905594A Abandoned CA2905594A1 (fr) | 2013-03-12 | 2014-03-11 | Compositions destinees a etre utilisees en traitement de troubles oculaires a l'aide de dipyridamole |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2968328A4 (fr) |
| JP (1) | JP6820658B2 (fr) |
| KR (2) | KR20210010638A (fr) |
| CN (1) | CN105188702B (fr) |
| AU (1) | AU2014229371B2 (fr) |
| BR (1) | BR112015022084A2 (fr) |
| CA (1) | CA2905594A1 (fr) |
| CL (1) | CL2015002627A1 (fr) |
| EA (1) | EA035966B1 (fr) |
| IL (1) | IL225179A (fr) |
| MX (1) | MX2015012716A (fr) |
| MY (1) | MY182591A (fr) |
| SG (2) | SG10201706937UA (fr) |
| WO (1) | WO2014141079A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2975000A1 (fr) * | 2015-01-28 | 2016-08-04 | Realinn Life Science Limited | Composes pour augmenter l'expression et la translocation nucleaire de pparg et utilisation therapeutique correspondante |
| US20180092776A1 (en) | 2016-09-30 | 2018-04-05 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
| WO2021001805A1 (fr) | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Formulations de dipyridamole stables et leurs procédés de préparation |
| WO2021001806A1 (fr) | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Formulations de dipyridamole stables avec des impuretés réduites |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07258084A (ja) * | 1994-03-17 | 1995-10-09 | Rohto Pharmaceut Co Ltd | ジピリダモールを必須成分とする眼圧降下剤 |
| US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| KR20080065704A (ko) * | 2005-11-09 | 2008-07-14 | 콤비네이토릭스, 인코포레이티드 | 의학적 이상의 치료 방법들, 조성물들, 및 키트들 |
| WO2010056710A1 (fr) * | 2008-11-11 | 2010-05-20 | Biovista, Inc. | Compositions et procédés pour traiter des maladies ophtalmiques |
| EP2363126A1 (fr) * | 2010-03-04 | 2011-09-07 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Composition comprenant une L-carnitine en tant que principe actif en combinaison avec le glucoside de l'hydroxykynurénine, pour la prévention et/ou le traitement de pathologies de l'oeil dues au rayonnement ultraviolet |
-
2013
- 2013-03-12 IL IL225179A patent/IL225179A/en active IP Right Grant
-
2014
- 2014-03-11 KR KR1020217001495A patent/KR20210010638A/ko not_active Application Discontinuation
- 2014-03-11 EA EA201591653A patent/EA035966B1/ru unknown
- 2014-03-11 CA CA2905594A patent/CA2905594A1/fr not_active Abandoned
- 2014-03-11 MX MX2015012716A patent/MX2015012716A/es unknown
- 2014-03-11 CN CN201480016302.6A patent/CN105188702B/zh not_active Expired - Fee Related
- 2014-03-11 BR BR112015022084A patent/BR112015022084A2/pt active Search and Examination
- 2014-03-11 SG SG10201706937UA patent/SG10201706937UA/en unknown
- 2014-03-11 WO PCT/IB2014/059645 patent/WO2014141079A1/fr active Application Filing
- 2014-03-11 EP EP14764673.1A patent/EP2968328A4/fr not_active Withdrawn
- 2014-03-11 MY MYPI2015002196A patent/MY182591A/en unknown
- 2014-03-11 KR KR1020157027571A patent/KR20150126021A/ko not_active IP Right Cessation
- 2014-03-11 SG SG11201507092QA patent/SG11201507092QA/en unknown
- 2014-03-11 JP JP2015562486A patent/JP6820658B2/ja active Active
- 2014-03-11 AU AU2014229371A patent/AU2014229371B2/en not_active Ceased
-
2015
- 2015-09-11 CL CL2015002627A patent/CL2015002627A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY182591A (en) | 2021-01-26 |
| EP2968328A4 (fr) | 2016-11-23 |
| JP2016514123A (ja) | 2016-05-19 |
| JP6820658B2 (ja) | 2021-01-27 |
| IL225179A0 (en) | 2013-06-27 |
| AU2014229371A1 (en) | 2015-10-29 |
| CN105188702A (zh) | 2015-12-23 |
| SG11201507092QA (en) | 2015-10-29 |
| CN105188702B (zh) | 2019-03-26 |
| MX2015012716A (es) | 2016-07-06 |
| IL225179A (en) | 2017-01-31 |
| CL2015002627A1 (es) | 2016-03-11 |
| EA035966B1 (ru) | 2020-09-07 |
| EP2968328A1 (fr) | 2016-01-20 |
| EA201591653A1 (ru) | 2017-05-31 |
| WO2014141079A1 (fr) | 2014-09-18 |
| BR112015022084A2 (pt) | 2017-07-18 |
| KR20150126021A (ko) | 2015-11-10 |
| AU2014229371B2 (en) | 2018-05-10 |
| KR20210010638A (ko) | 2021-01-27 |
| SG10201706937UA (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5583310B2 (ja) | 眼球の症状の予防及び治療のための眼科用製剤 | |
| EP1904108B1 (fr) | Formulation ophthalmologique comprenant du methylsulfonylmethane and ciprofloxacine | |
| KR20100067684A (ko) | 약물 전달을 위한 비히클로서의 수불혼화성 물질 | |
| JP2009501726A (ja) | 眼科学的活性剤の製剤とその投与の方法 | |
| US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
| CA2801145A1 (fr) | N-acetyl-dl-leucine, medicament neuroprotecteur et retinoprotecteur | |
| RU2602738C2 (ru) | Комбинация фолиевой кислоты и рамиприла: цитопротекторные, нейропротекторные и ретинопротекторные офтальмологические композиции | |
| AU2014229371B2 (en) | Compositions for use in treating eye disorders using dipyridamole | |
| US9254289B2 (en) | Methods for treating eye disorders using dipyridamole | |
| RU2485939C1 (ru) | Офтальмологический препарат в виде глазных капель, содержащий дисульфирам и таурин | |
| US10322129B2 (en) | Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same | |
| CN116981457A (zh) | 有效预防、控制和根除老花眼的低浓度剂量的协同眼科组合物 | |
| JP7197112B2 (ja) | 水泡性角膜症治療用医薬組成物 | |
| US8853257B2 (en) | Succinimide derivatives as ocular hypotensive agents | |
| TW202002980A (zh) | 選擇性syk抑制劑之使用方法及醫藥組合物 | |
| US20140213605A1 (en) | Methods for treating eye disorders using opioid receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190115 |
|
| FZDE | Discontinued |
Effective date: 20230104 |
|
| FZDE | Discontinued |
Effective date: 20230104 |